Niacin and Progression of CKD

Elani Streja, Csaba Kovesdy, Dan A. Streja, Hamid Moradi, Kamyar Kalantar-Zadeh, Moti L. Kashyap

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population.

Original languageEnglish (US)
Pages (from-to)785-798
Number of pages14
JournalAmerican Journal of Kidney Diseases
Volume65
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Niacin
Chronic Renal Insufficiency
HDL Lipoproteins
Dyslipidemias
Glomerular Filtration Rate
Triglycerides
Dietary Phosphorus
VLDL Cholesterol
Oxidants
LDL Cholesterol
Phosphorus
HDL Cholesterol
Population
Gastrointestinal Tract
Cardiovascular Diseases
Therapeutics
Clinical Trials
Inflammation
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Streja, E., Kovesdy, C., Streja, D. A., Moradi, H., Kalantar-Zadeh, K., & Kashyap, M. L. (2015). Niacin and Progression of CKD. American Journal of Kidney Diseases, 65(5), 785-798. https://doi.org/10.1053/j.ajkd.2014.11.033

Niacin and Progression of CKD. / Streja, Elani; Kovesdy, Csaba; Streja, Dan A.; Moradi, Hamid; Kalantar-Zadeh, Kamyar; Kashyap, Moti L.

In: American Journal of Kidney Diseases, Vol. 65, No. 5, 01.05.2015, p. 785-798.

Research output: Contribution to journalReview article

Streja, E, Kovesdy, C, Streja, DA, Moradi, H, Kalantar-Zadeh, K & Kashyap, ML 2015, 'Niacin and Progression of CKD', American Journal of Kidney Diseases, vol. 65, no. 5, pp. 785-798. https://doi.org/10.1053/j.ajkd.2014.11.033
Streja E, Kovesdy C, Streja DA, Moradi H, Kalantar-Zadeh K, Kashyap ML. Niacin and Progression of CKD. American Journal of Kidney Diseases. 2015 May 1;65(5):785-798. https://doi.org/10.1053/j.ajkd.2014.11.033
Streja, Elani ; Kovesdy, Csaba ; Streja, Dan A. ; Moradi, Hamid ; Kalantar-Zadeh, Kamyar ; Kashyap, Moti L. / Niacin and Progression of CKD. In: American Journal of Kidney Diseases. 2015 ; Vol. 65, No. 5. pp. 785-798.
@article{ad11c7705c3b4f85b60fade10a6a029b,
title = "Niacin and Progression of CKD",
abstract = "Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population.",
author = "Elani Streja and Csaba Kovesdy and Streja, {Dan A.} and Hamid Moradi and Kamyar Kalantar-Zadeh and Kashyap, {Moti L.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1053/j.ajkd.2014.11.033",
language = "English (US)",
volume = "65",
pages = "785--798",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Niacin and Progression of CKD

AU - Streja, Elani

AU - Kovesdy, Csaba

AU - Streja, Dan A.

AU - Moradi, Hamid

AU - Kalantar-Zadeh, Kamyar

AU - Kashyap, Moti L.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population.

AB - Niacin is the oldest drug available for the treatment of dyslipidemia. It has been studied extensively and tested in clinical trials of atherosclerotic cardiovascular disease prevention and regression in the general population, but not specifically in patients with chronic kidney disease (CKD), who are at extremely high residual risk despite current therapy. Despite the current controversy about recent trials with niacin, including their limitations, there may be a place for this agent in select patients with CKD with dyslipidemia. Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract. These effects may slow glomerular filtration rate decline and ultimately improve CKD outcomes and prevent cardiovascular risk. This review presents the clinically relevant concept that niacin holds significant potential as a renoprotective therapeutic agent. In addition, this review concludes that clinical investigations to assess the effect of niacin (in addition to aggressive low-density lipoprotein cholesterol lowering) on reduction of cardiovascular events in patients with CKD with very low HDL cholesterol (or those with identified dysfunctional HDL) and elevated triglyceride levels need to be considered seriously to address the high residual risk in this population.

UR - http://www.scopus.com/inward/record.url?scp=84929028625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929028625&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2014.11.033

DO - 10.1053/j.ajkd.2014.11.033

M3 - Review article

VL - 65

SP - 785

EP - 798

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -